

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32969	APPLICATION NO. 10/501,317
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Bromidge et al.	
		FILING DATE February 22, 2005	GROUP 1625

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US20050203079 A1	9/15/05	Damiani et al.	514	212.03	
	US20060205788 A1	9/14/06	Damiani et al.	514	326	

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 94/04533 A1	3/3/94	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Jenck et al., <i>Exp. Opin. Invest. Drugs</i> , <u>7</u> : 1587-1599 (1998).
	Lôo et al.; <i>Int. Clin. Psychopharmacol.</i> , <u>17</u> : 239-247 (2002).
	Papp et al., <i>Neuropsychopharmacology</i> , <u>28</u> : 694-703 (2003).
	Cremers et al., <i>Neuropsychopharmacology</i> , <u>29</u> : 1782-1789 (2004).
	Dremencov et al., <i>Neuropharmacology</i> , <u>48</u> : 34-42 (2005).
	Goodacre et al., <i>Bioorg. Med. Chem. Lett.</i> , <u>15</u> : 4989-4993 (2005).
	Office Action in copending U.S. Application #10/511,769 dated 3/10/2008
EXAMINER  /Binta Robinson/	DATE CONSIDERED  10/14/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.